Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...

Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin (HbA1c) at three months 1 Reductions in HbA1c ...

Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...

ABBOTT PARK, Ill., June 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2 ...

Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out ...

The FreeStyle Libre 3 glucose monitoring system (Abbott) has been granted a CE mark for use by people with diabetes in the countries of the European Union (EU). The next-generation FreeStyle Libre 3 ...

SAN FRANCISCO--(BUSINESS WIRE)--Today, Nutrino, (www.nutrino.co) announces the collaboration with the LibreLink 1, 2 application, designed for Abbott’s FreeStyle Libre Flash Glucose Monitoring system.

MARD is considered the simplest measurement of sensor accuracy 2 and represents the difference between a CGM system's glucose readings and a reference blood glucose measurement. The lower the MARD, ...

First and only continuous glucose monitoring system to be nationally reimbursed in France for people who use once-daily (basal) insulin 1 Expanded reimbursement facilitates wider access to continuous ...